Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis.
Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%.
Considering that Bcl-2 inhibitor is effective for AL amyloidosis with t(11; 14) and the
median hematologic onset time of DBD is 7 days. We design a a prospective study on AL
amyloidosis with t(11; 14). All patients receive DBD at the beginning. Patient will receive
DBD for at least 6 cycles if achieve rapid hematologic response at day 7, while other
patients will receive daratumumab, venetoclax and dexamethasone.